Q32 Bio Stock Performance
| QTTB Stock | 24.55 2.49 9.21% |
The firm owns a Beta (Systematic Risk) of 1.0, which implies a somewhat significant risk relative to the market. Q32 Bio returns are very sensitive to returns on the market. As the market goes up or down, Q32 Bio is expected to follow. At this point, Q32 Bio has a negative expected return of -0.55%. Please make sure to check Q32 Bio's standard deviation, kurtosis, period momentum indicator, as well as the relationship between the maximum drawdown and day median price , to decide if Q32 Bio performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Q32 Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (9.21) | Five Day Return (25.49) | Year To Date Return 126.06 | Ten Year Return (92.69) | All Time Return (92.69) |
Last Split Factor 1:18 | Last Split Date 2024-03-26 |
1 | Q32 Bios Stock Hits 52 Week High As Wells Fargo Initiates With Lofty Price Target - AskTraders | 09/11/2024 |
2 | Acquisition by Lundberg Sven Ante of 1316 shares of Q32 Bio at 44.4 subject to Rule 16b-3 | 09/25/2024 |
3 | Bank of New York Mellon Corp Invests 315,000 in Q32 Bio Inc. - MarketBeat | 09/26/2024 |
4 | Q32 Bios SWOT analysis emerging biotech stock targets inflammatory diseases - Investing.com India | 09/30/2024 |
5 | Disposition of 13300 shares by Shelia Violette of Q32 Bio at 3.12 subject to Rule 16b-3 | 10/08/2024 |
6 | Disposition of 4361 shares by Shelia Violette of Q32 Bio at 3.12 subject to Rule 16b-3 | 10/11/2024 |
7 | Acquisition by Shelia Violette of 6000 shares of Q32 Bio at 7.29 subject to Rule 16b-3 | 10/15/2024 |
8 | Oppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical Outlook | 10/16/2024 |
9 | Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/07/2024 |
10 | Q32 Bio Trading Down 0.9 percent - Heres Why - MarketBeat | 11/22/2024 |
| Begin Period Cash Flow | 34 M |
Q32 |
Q32 Bio Relative Risk vs. Return Landscape
If you would invest 3,782 in Q32 Bio on August 27, 2024 and sell it today you would lose (1,327) from holding Q32 Bio or give up 35.09% of portfolio value over 90 days. Q32 Bio is currently does not generate positive expected returns and assumes 4.8935% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Q32, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Q32 Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Q32 Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Q32 Bio, and traders can use it to determine the average amount a Q32 Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1131
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | QTTB |
Estimated Market Risk
| 4.89 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.55 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Q32 Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Q32 Bio by adding Q32 Bio to a well-diversified portfolio.
Q32 Bio Fundamentals Growth
Q32 Stock prices reflect investors' perceptions of the future prospects and financial health of Q32 Bio, and Q32 Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Q32 Stock performance.
| Operating Margin | 5.18 % | ||||
| Current Valuation | 468.77 M | ||||
| Shares Outstanding | 12.06 M | ||||
| Price To Book | 16.61 X | ||||
| Revenue | 1.16 M | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (112.96 M) | ||||
| Total Debt | 1.32 M | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (96.23 M) | ||||
| Earnings Per Share | (4.50) X | ||||
| Market Capitalization | 556.56 M | ||||
| Total Asset | 306.12 M | ||||
| Retained Earnings | (542.1 M) | ||||
About Q32 Bio Performance
By analyzing Q32 Bio's fundamental ratios, stakeholders can gain valuable insights into Q32 Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Q32 Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Q32 Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 221.19 | 232.25 | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.55) | (1.47) |
Things to note about Q32 Bio performance evaluation
Checking the ongoing alerts about Q32 Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Q32 Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Q32 Bio generated a negative expected return over the last 90 days | |
| Q32 Bio has high historical volatility and very poor performance | |
| Q32 Bio has high likelihood to experience some financial distress in the next 2 years | |
| Q32 Bio was previously known as Homology Medicines and was traded on NASDAQ Exchange under the symbol FIXX. | |
| The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (112.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Q32 Bio generates negative cash flow from operations | |
| About 74.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Q32 Bio Trading Down 0.9 percent - Heres Why - MarketBeat |
- Analyzing Q32 Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Q32 Bio's stock is overvalued or undervalued compared to its peers.
- Examining Q32 Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Q32 Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Q32 Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Q32 Bio's stock. These opinions can provide insight into Q32 Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Q32 Stock analysis
When running Q32 Bio's price analysis, check to measure Q32 Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Q32 Bio is operating at the current time. Most of Q32 Bio's value examination focuses on studying past and present price action to predict the probability of Q32 Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Q32 Bio's price. Additionally, you may evaluate how the addition of Q32 Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |